myelosuppress particular neutropenia anemia seriou complic malign treatment neutropenia make patient vulner potenti life-threaten infect result dose reduct delai plan chemotherapi signific detriment effect tumour respons surviv anemia associ rang debilit effect sever impair patient' qol addit evid recogn anemia poor prognost indic associ reduc treatment efficaci reduct durat sever neutropenia anemia possibl initi appropri growth factor first subsequ cycl chemotherapi improv growth factor support agent pegfilgrastim darbepoetin alfa potenti improv manag chemotherapi-induc neutropenia anemia thrombopoietin current clinic trial assess potenti role treatment thrombocytopenia patient cancer
collect activ retrospect survei case hematolog malign newli diagnos time period 1974-1993 resid popul sardinia diagnosi deem valid consult clinic record 7264 collect case number newli diagnos case year doubl 20-year period investig strike increas partial account ag popul inde ag-specif ag-adjust rate most increas period hodgkin diseas chronic myeloid leukemia cml acut lymphoblast leukemia notabl except observ increas rate like larg part fictiti due easier access health care system meantim improv diagnost effici particularli evid chronic lymphocyt leukemia cll multipl myeloma other myelo- lympho-prolif disord relev declin 1984-1989 like true increas occurr evidenc non-hodgkin lymphoma nhl similarli lesser extent doubt myelodysplasia md acut myeloid leukemia aml studi period type present ag sex distribut ag-adjust rate show minor differ report western countri argument emerg suggest genet peculiar sardinian popul affect occurr confound effect improv diagnost effici prevent reliabl assess influenc incid environment socio-econom chang rel recent time occur sardinia
nuclear factor kappa nf-kappab famili transcript factor plai major role inflamm immun stress respons oncogenesi cell migrat angiogenesi aberr activ nf-kappab shown contribut intrins induc drug resist numer cancer includ multipl myeloma express nf-kappab-respons target will vari depend cellular context type induc regul nf-kappab activ occur multipl level involv ikappab kinas ikk complex member ikappab famili recruit heterolog transcript factor coactiv nf-kappab post-translat modif p65 articl highlight regulatori mechan respons constitut nf-kappab activ provid justif target-base therapi nf-kappab multipl myeloma
greig cephalopolysyndactyli gcp omim 175700 autosom domin condit caus mutat gene gli3 locat 7p13 date sever case delet transloc involv locu report patient gcp gli3 transcript factor gli-kruppel gene famili implic three distinct entiti gcp pallist-hall syndrom postaxi polydactyli type zinc finger protein subfamili member gene znfn1a1 omim 603023 7p12 code lymphoid-restrict zinc finger transcript factor znfn1a1 call ikaro regul lymphocyt differenti associ develop childhood leukemia present case 9-year-old latin-american boi refer stem cell transplant becaus recurr acut lymphoblast leukemia evalu found dysmorph featur consist gcp includ promin forehead down-slant palpebr fissur 1-2-3 toe syndactyli broad thumb first toe mild development delai develop year ag chromosom analysi bone marrow fibroblast cell show interstiti delet chromosom arm del p11.2p14 cell respect perform fish analysi bac clone contain znfn1a1 gene demonstr contain delet segment knowledg first report patient gcp leukemia hypothes constitut delet znfn1a1 gene patient result increas risk lymphoid malign
cytogenet abnorm 12q12-q14 chromosom locu rare detect acut lymphoblast leukemia examin submicroscop delet locu analyz adult precursor t-cell case [27 philadelphia chromosom -neg b-cell ph-neg b-cell express on two myeloid marker ph-posit b-cell t-cell all] us panel microsatellit mst marker span 12q12-q14.3 region statu mst marker evalu us polymeras chain reaction perform fluoresc-label primer autom fragment analysi mst marker analys show submicroscop delet 12q14.3 locu case frequenc delet highest ph-neg b-cell compar ph-neg b-cell express myeloid marker ph-posit b-cell t-cell delet frequenc mst marker along 12q12-q14.3 locu suggest target gene delet locat 170-kb region border marker d12s1504 approxim upstream hmga2 d12s1509 intron hmga2 12q14.3 locu submicroscop delet 12q14.3 locu plai role pathogenesi particularli ph-neg precursor b-cell
purpos diosgenin steroid sapogenin estrogen antitumor properti order elucid mechan antiprolif activ investig effect cell cycl apoptosi human chronic myelogen leukemia k562 cell method cell viabil assess via mtt assai apoptosi investig term nuclear morpholog dna fragment phosphatidylserin extern cell cycl analysi perform via stain flow cytometri fcm western blot immunofluoresc method us determin level p53 cell cycl-relat protein bcl-2 famili member fcm us estim chang mitochondri membran potenti mmp intracellular ca2+ concentr reactiv oxygen speci ro gener result cell cycl analysi show diosgenin caus g2/m arrest independ p53 level cyclin p21cip1/waf1 decreas wherea cdc2 level increas subsequ apoptosi demonstr dramat activ caspas-3 dramat declin intracellular ca2+ concentr observ initi event process cell cycl arrest apoptosi follow hyperpolar depolar mmp gener ro observ progress apoptosi antiapoptot bcl-2 bcl-xl protein downregul wherea proapoptot bax upregul conclus diosgenin inhibit k562 cell prolifer via cell cycl g2/m arrest apoptosi disrupt ca2+ homeostasi mitochondri dysfunct plai vital role
purpos intrins p-glycoprotein p-gp express gut limit paclitaxel uptak bioavail administ oral interleukin-2 report p-gp modul vitro vivo mice work describ here effect interleukin-2 pretreat pharmacokinet toxic paclitaxel oral administ investig method pharmacokinet studi mice alloc two group receiv mg/kg paclitaxel oral rout alon 16.5 microg human recombin interleukin-2 ril2 intraperiton rout twice daili dai paclitaxel pharmacokinet profil analys first bailer method us compartment approach toxic studi swiss mice alloc three group receiv paclitaxel mg/kg oral ril2 alon 16.5 microg i.p twice daili dai control group both treatment haematolog paramet measur three group compar us bailer method bonferroni correct appli test result complex absorpt paclitaxel reveal bailer method show mean area under curv auc valu 0-24 significantli differ two group despit trend reduc auc pretreat group auc 0-0.5 significantli higher group pretreat ril2 repres fraction total exposur result confirm compartment analysi elimin rate constant remain same across both group ril2 increas paclitaxel absorpt min oral intak drug enhanc overal exposur conclus found 3-dai pretreat ril2 vivo inhibitori effect p-gp activ short period oral dose paclitaxel result encourag investig effect ril2 overal exposur paclitaxel hand seem joint administr two drug increas risk myelosuppress worth know treat advanc cancer
background paclitaxel formul taxol bristol-myer squibb on most effect anticanc agent us todai howev associ seriou side effect believ caus cremophor us formul aim evalu cytotox activ paclitaxel formul pacliex develop oasmia pharmaceut uppsala sweden mix micel prepar amphiphil synthet deriv retino acid replac cremophor el/ethanol vehicl method studi three model system us evalu cytotox activ pacliex paclitaxel prepar cytotox activ pacliex taxol paclitaxel ethanol investig panel ten human tumor cell line us fluorometr microcultur cytotox assai fmca low- high- prolifer vitro hollow fiber model two cell line leukemia ccrf-cem myeloma rpmi 8226/s cell line us assess cytotox activ three formul vivo hollow fiber model two cell line us assess pacliex taxol activ [3-4 5-dimethylthiazol-2-yl]-2 5-diphenyltetrazolium bromid mtt assai util analyz vitro vivo hollow fiber data result pacliex somewhat effect taxol sensit cell line activ taxol pronounc resist cell line due addit effect vehicl us three formul show similar activ both low- high-prolifer vitro hollow fiber cultur vivo hollow fiber cytotox activ pacliex similar taxol put result togeth found three formul similar vitro vivo activ conclus three vitro vivo model confirm similar cytotox activ pacliex taxol consid pacliex interest altern cremophor el-free formul paclitaxel
investig polyomaviru infect pregnanc link develop neuroblastoma child serum sampl 115 index mother pregnanc child eventu develop neuroblastoma identifi match serum sampl control mother per index mother sampl test specif igg igm antibodi viru us enzym immunoassai base purifi yeast-express viru-like particl vlp serum sampl well neuroblastoma cell line analyz us real time taqman pcr detect quantif viru dna viru igg seropreval similar among index mother control mother [or 0.8 confid interv 0.5-1.3] viru igm associ neuroblastoma risk 0.6 0.2-1.9 viru associ neither igg 0.9 0.6-1.4 nor igm 0.9 0.4-1.9 serum sampl neuroblastoma cell line neg bkv dna summari comprehens cohort us both serolog polyomaviru dna detect found evid associ bkv jcv polyomavirus neuroblastoma
background patient down syndrom standard risk acut lymphoblast leukemia all-ds report inferior event free ef overal surviv compar patient all-nd procedur compar preval favor unfavor clinic biolog featur toxic outcom all-ds all-nd cohort 174 elig patient sr-all enrol ccg-1952 result fifti-nine patient all-ds patient like favor hyperdiploidi tripl trisomi chromosom tel-aml1 rearrang unfavor t-cell hypodiploidi advers transloc biolog featur toxic occur significantli number dai hospit significantli greater all-ds all-nd all-ds patient inferior 4-year ef compar nd cohort howev ef equival comparison exclud all-nd favor biolog featur significantli inferior all-ds conclus absenc favor biolog featur all-ds contribut differ ef previous observ nd sr-all cohort
background life-threaten pulmonari complic coincid cell lysi earli chemotherapi mimic system inflammatori respons syndrom sir report patient acut myeloid leukemia aml method review record patient novo aml exclud down syndrom treat institut 1991 2002 determin preval sever sir grade 3/4 pulmonari complic identifi aml subtyp associ sever sir examin role cell lysi compar leukocyt reduct aml subtyp affect sever sir unaffect subtyp result 155 patient m4eo experienc sever pulmonari complic attribut tumor lysi met criteria sever sir show clear evid infect four requir pressor support sever hypotens sever sir significantli common myelomonocyt monocyt aml m4/m4eo/m5 subtyp 0.010 significantli common m4eo m4/m5 0.008 among 112 case inform avail leukocyt reduct significantli greater patient m4/m4eo/m5 among other first dai chemotherapi 0.015 leukocyt reduct significantli rapid among patient sever sir among other 0.008 conclus patient m4/m4eo/m5 aml especi m4eo experi life-threaten cardiopulmonari complic tumor lysi meet criteria sever sir observ reflect rapid cell reduct uniqu biologi subtyp
l-asparaginas kei compon antileukem therapi children acut lymphoblast leukemia pancreat note complic 2-16 patient undergo treatment l-asparaginas varieti pediatr neoplasm most case pancreat associ l-asparaginas toxic self-limit respond favor nasogastr decompress intraven hyperaliment howev rare instanc hemorrhag pancreat necrosi occur l-asparaginas-induc pancreat uncommon potenti lethal complic treatment leukemia present pediatr patient leukemia sever l-asparaginas-induc necrot pancreat treat successfulli percutan drainag us flush infect necrot part
studi suggest 20-fold increas risk leukemia individu down syndrom most increas risk appear first few decad life highest incid children year ag unknown children down syndrom increas risk leukemia respect environment exposur will import investig risk factor associ childhood leukemia gener includ diagnost x-rai pesticid occup exposur well experi common children down syndrom includ routin medic screen test increas suscept infect increas vitamin defici
background dapson commonli us pneumocysti carinii pneumonia pcp prophylaxi immunocompromis patient methemoglobinemia known complic dapson true frequenc pathogenesi childhood cancer patient unknown addition practic guidelin evalu manag dapson-induc methemoglobinemia avail procedur studi children acut lymphoblast leukemia receiv dapson pcp prophylaxi determin frequenc methemoglobinemia correl occurr cytochrom reductas cb5r enzym level ten children receiv trimethoprim-sulfamethaxazol tmp-smx studi control patient underw physic examin puls oximetri methemoglobin methb estim commerci avail assai us measur cb5r level result three patient receiv dapson develop symptomat methemoglobinemia averag durat dapson prophylaxi prior diagnosi 6.6 week rang 3.5-10 week mean methb level symptomat patient 11.67 confid interv 0-25.79 rang 7-18 1.37 0.6-2.14 rang 0.02-3 asymptomat patient 0.09 wherea mean methb level control group 0.54 0.35-0.73 rang 0.1-0.8 asymptomat control &lt 0.0001 mean cb5r level symptomat patient 8.6 iu/g 3.4-13.7 rang 6.9-10.9 compar 12.5 iu/g 11.1-13.9 rang 10.8-14.6 asymptomat patient 0.06 two symptomat patient cb5r level normal consist heterozygos parent studi cb5r level suggest carrier state on patient's parent conclus heterozygos cb5r defici pre-dispos methemoglobinemia thrice-weekli regimen dapson individu avoid subsequ exposur oxid agent possibl children tend symptomat low level methb delai detect methemoglobinemia henc frequent monitor patient receiv dapson recommend monitor guidelin dapson prophylaxi propos
infant constitut trisomi increas risk develop transient acut megakaryoblast leukemia amkl mutat gata1 identifi trisomi patient amkl lesion thought initi event virtu presenc transient leukemia transient leukemia observ phenotyp normal infant albeit much commonli almost infant mosaic trisomi clinic cours transient leukemia recapitul observ constitut trisomi report phenotyp normal infant tetrasomi transient leukemia gata1 mutat exon trisomi mosaic restrict hematopoiet tissu two year diagnosi low level trisomi persist peripher blood resolv 2.5 year diagnosi gata1 mutat detect follow-up literatur review identifi phenotyp normal infant transient leukemia nineti-on percent observ three receiv chemotherapi diagnosi transient leukemia nineteen percent develop acut leukemia four continu remiss two di transient leukemia trisomi mosaic recapitul condit observ constitut trisomi biolog clinic level infant follow develop acut leukemia
recogn chromosom abnorm childhood leukemia link both leukemogenesi segreg patient prognost treatment group best exemplifi case children down syndrom significantli higher risk develop leukemia compar non-ds children distinct treatment outcom particularli case acut myeloid leukemia aml high event-free surviv ef rate aml patient particular patient megakaryocyt leukemia amkl least part reflect increas sensit cytosin arabinosid ara-c secondari increas express chromosom 21-local gene cystathionin-beta-synthas potenti global mechan increas suscept cell undergo apoptosi somat mutat x-link transcript factor gene gata1 detect uniformli exclus amkl case lead alter express gata1 target gene alter metabol drug includ ara-c hyperdiploid acut lymphoblast leukemia cell extra copi chromosom gener higher level activ methotrex mtx metabolit mtx polyglutam account increas intracellular transport mtx via reduc folat carrier rfc gene local chromosom account increas mtx-associ toxic patient microarrai technolog lead identif addit gene target link treatment respons specif cytogenet leukemia subgroup
physician known decad children down syndrom predispos develop transient myeloprolif disord tmd acut megakaryoblast leukemia amkl question regard disord remain unresolv first relationship tmd amkl second specif genet alter contribut leukem process final factor lead increas predisposit myeloid disord review will summar import insight biologi tmd amkl gain recent discoveri gata1 gene encod essenti hematopoiet transcript factor mutat leukem blast patient malign addit will discuss whether assai presenc gata1 mutat aid diagnosi relat megakaryoblast leukemia futur research aim defin activ mutant gata-1 protein identifi interact factor encod chromosom will like lead greater understand intrigu leukemia
past decad seri clinic report describ experi down syndrom children treat acut myeloid leukemia aml wherea prior first report earli 1980's felt children aml poor outcom clinic trial conclud better outcom non-ds nd children aml recent report clear children better outcom util intens chemotherapi regimen toler intens regimen well nd children review focus six multi-institut report describ aml experi order better ascertain chemotherapi combin us futur children regimen vari intens similar outcom gener remiss rate approxim event-free surviv ef approxim 70-80 most recent clinic trial larg enough explor prognost factor specif children identifi younger children fair significantli better older children aml uniqu differ comparison nd children highlight significantli better outcom children like repres combin uniqu aml children heighten sensit cytarabin aml cell futur trial focu ag-stratifi approach exploit greater sensit aml cytarabin
children down syndrom 10- 20-fold increas risk develop leukemia particularli acut megakaryocyt leukemia newborn trisomi mosaic exhibit particularli uniqu form leukemia histor associ high rate spontan remiss transient leukemia shown clonal prolifer blast cell exhibit megakaryocyt featur true incid remain determin present infant clinic well incident find abnorm blood count circul blast peripher blood howev approxim case diseas sever life-threaten manifest hydrop faetali multipl effus liver multi-organ system failur result death children enter spontan remiss 13-33 found develop subsequ acut megakaryoblast leukemia usual first year life left untreat fatal uniqu newborn subject recent clinic cooper group trial well biolog genet research effort summar here known clinic biolog cytogenet featur associ
purpos studi determin effect structur chang intestin disposit isoflavon elucid mechan respons transport phase isoflavon conjug transport metabol six isoflavon i.e genistein daidzein glycitein formononetin biochanin prunetin studi human intestin caco-2 model matur caco-2 cell lysat glucuronid main metabolit intact caco-2 cell isoflavon except prunetin mainli sulfat addit 7-hydroxi group main site glucuronid wherea 4'-hydroxi group on possibl site sulfat glucuronid isoflavon except biochanin prefer excret basolater side wherea sulfat metabolit except genistein glycitein mainli excret apic side polar excret most isoflavon conjug inhibit multidrug resist-relat protein mrp inhibitor leukotrien 0.1 micro organ anion transport oat inhibitor estron sulfat micro format excret rate isoflavon determin simultan result show format serv rate-limit step isoflavon conjug both glucuronid sulfat except genistein glucuronid compar excret format rate conclus intestin disposit isoflavon structur depend polar mediat mrp oat format gener serv rate-limit step cellular excret conjug isoflavon caco-2 cell cultur model
present paper report molecular cytogenet studi abnorm associ q24 q32 adult common acut lymphoblast leukemia case fab-l2 morpholog us appropri molecular cytogenet probe allow detect differ subclon show heterogen chromosom abnorm complex pattern rearrang consist transloc duplic invers observ breakag-fusion-bridg cycl jump transloc hypothes involv gener larg number aberr detect
mutat dysregul relat homeobox gene occur leukemia us rt-pcr screen member ehg famili homeobox gene compris en1 2q14 gbx2 2q36 en2 gbx1 hlxb9 7q36 dysregul acut myeloid leukemia aml cell line indic chromosom breakpoint site on ehg-famili gene express hlxb9 cell line gdm-1 aml-m4 karyotyp analysi gdm-1 reveal uniqu q23 q35 present patient fluoresc situ hybrid analysi show chromosom breakpoint close region upstream hlxb9 7q36 region rearrang certain aml patient 6q23 upstream myb gene activ leukemia detail express analysi suggest ectop activ hlxb9 occur via juxtaposit region upstream myb highli express gdm-1 data identifi cell line model novel leukem transloc involv myb hlxb9 implic hlxb9 leukemogenesi
q23 p13 result fusion tcf3 previous e2a 19p13 pbx1 1q23 on most common transloc acut lymphoblast leukemia balanc unbalanc der occasion case coexist der -posit clone describ gener assum unbalanc form aris balanc through loss deriv chromosom follow duplic normal homologu prove least two mechan possibl format der initi trisomi follow transloc subsequ loss der rearrang phase cell cycl deriv chromosom end separ daughter cell differ altern distinguish investig marker proxim breakpoint 1q23 becaus expect lead differ allel pattern loss heterozygos result presenc uniparent disomi upd -both copi chromosom deriv on parent-for chromosom present der -harbor case aris via duplic pathwai on-third case aris via trisomi pathwai none der form via pathwai studi us quantit fluoresc pcr polymorph microsatellit marker investig chromosom two four der -posit all none der case displai upd chromosom exclud aberr aris through duplic pathwai becaus previou find case coexist der clone difficult explain transloc origin present result suggest unbalanc der aris initi trisomi follow transloc loss deriv chromosom
defect dna repair report risk factor variou malign genet polymorph dna repair gene thought result differ phenotyp featur compar wild type genet polymorph xrcc1 gene through alter protein structur lead defect function dna polbeta parp lig3 enzym result defect dna repair increas risk childhood acut lymphoblast leukemia role dna repair gene xrcc1 suscept childhood howev wide studi data exist indian children pilot studi through us pcr rflp confirm dna sequenc shown increas risk among children xrcc1 codon 194 399 variant genotyp among three variant associ codon 399 variant risk appear signific risk higher male codon 194 399 polymorph femal howev relat found presenc variant genotyp treatment outcom
order identifi regulatori gene involv develop apoptosi-resist phenotyp patient chemotherapi refractori b-cell chronic lymphocyt leukemia b-cll express apoptosi-regul gene b-cll cell quantifi us cdna arrai rt-pcr data obtain compar group b-cll patient nonprogress indol previous untreat diseas leukem cell sensit vitro fludarabin-induc apoptosi refer sensit b-cll sb-cll progress chemotherapi refractori diseas leukem cell resist vitro fludarabin-induc apoptosi refer resist b-cll rb-cll perform supervis cluster gene most strongli discrimin rb-cll sb-cll small group gene identifi bfl-1 strongest discrimin gene &lt 0.05 higher express rb-cll group apoptosi-regul gene modul induct apoptosi serum depriv vitro similar manner case studi howev bfl-1 preferenti downregul sb-cll compar rb-cll &lt 0.05 conclud bfl-1 import regul b-cll apoptosi contribut diseas progress resist chemotherapi repres futur potenti therapeut target
background recombin interleukin -11 thrombopoiet growth factor purpos studi assess toxic safeti efficaci low-dose recombin il-11 patient bone marrow failur bmf patient method patient bmf due myelodysplast syndrom md graft failur chemotherapi aplast anemia treat patient requir platelet count &lt platelet count &lt absolut neutrophil count &lt hemoglobin valu &lt g/dl treatment consist daili il-11 dose mug/kg subcutan follow 2-week rest period two induct cours given respond receiv mainten therapi result thirti-three patient md prolong thrombocytopenia stem cell transplant chemotherapi evalu median ag year rang 5-85 three patient poor risk cytogenet nine patient respond il-11 six md three three patient treat il-11 alon il-11 togeth growth factor show multilineag recoveri median time respons 0.9 month rang 0.3-11 factor associ higher respons rate univari analysi ag year 0.008 diagnosi md versu 0.025 creatinin level mg/dl 0.0004 median respons durat month rang 1.4-34.5+ amongst respond median increment platelet count 111 rang 43-165 most common side-effect grade 1-2 lower extrem edema conjunctiv inject fatigu grade toxic includ arrhythmia transient ischem attack ten patient side-effect conclus low-dose il-11 activ patient bmf gener well toler
background larg cell variant small cell carcinoma hypercalcem type scc-ht extrem rare report case involv ovari on primari periton origin describ convinc neuroendocrin granul illustr case 35-year-old woman underw exploratori laparotomi leiomyoma intraop impress periton carcinomatosi confirm frozen section tah/bso debulk/omentectomi follow tumor present pelvic/abdomin peritoneum normal-size ovari free tumor grossli tumor featur larg cell variant scc-ht describ ovari furthermor unequivoc neuroendocrin granul present patient receiv standard chemotherapi scc month ned conclus scc-ht consid differenti diagnosi primari neoplasm peritoneum
background coccidioidomycosi second most common endem fungal infect southwestern unit state rare fungal infect exhibit symptom suggest periton malign ascit abdomin pelvic mass case present case involv 51-year-old woman present abdomin pain ascit elev serum ca-125 level 1995 underw total abdomin hysterectomi bilater salpingo-oophorectomi final patholog reveal coccidioidomycosi prolong treatment fluconazol fungal symptom resolv complet conclus patient coccidioidomycosi good prognosi optim diagnos treat ascit elev serum ca-125 level associ coccidioidomycosi document literatur extrem rare abdomin coccidioidomycosi consid differenti diagnosi patient present ascit elev serum ca-125 level
dendrit cell recent us vaccin stimul tumour-specif immun variou type cancer data interact tumour cell deriv head neck cancer avail studi investig effect head neck squamou cell carcinoma hnscc cell line matur found immatur effici internalis necrot cell live apoptot tumour cell apoptot cell induc partial matur abl stimul secret il-12 contrast necrot tumour cell prepar three hnscc cell line induc matur phenotyp il-12 product moreov necrot cell synergist augment stimulatori effect monocyt-condit medium matur dc-base vaccin util necrot tumour cell sourc tumour antigen combin inflammatori stimulu seem suitabl strategi adjuv immunotherapi hnscc
oral leukoplakia import premalign lesion oral mucosa treat lesion prophylact co2 laser evapor period 1976 2001 group 200 patient 282 oral leukoplakia treat co2 laser evapor follow period 1-219 month mean 251 treat leukoplakia 89.0 show recurr twenti eight 9.9 local recurr observ 168 month treatment three 1.1 squamou cell carcinoma occur treat area respect month co2 laser evapor larg studi long follow show laser treatment good prophylact treatment oral leukoplakia
squamou cell cancer head neck scchn associ product pro-inflammatori pro-angiogen cytokin hypothes cytokin serum level will correl tumor volum aggress investig interleukin-8 il-8 vascular endotheli growth factor vegf epiderm growth factor receptor egfr scchn patient popul consist normal irradi control patient newli diagnos scchn patient recurr metastat diseas pretreat sera studi elisa serum il-8 level oppos vegf egfr consist elev patient recurr metastat diseas differ mean serum il-8 compar control signific 0.02 serum level il-8 consist elev patient recurr metastat scchn elev level correl advanc aggress diseas intens studi il-8 biomark scchn warrant
background activ mutat flt3 identifi multipl myeloid malign two type activ mutat describ intern tandem duplic flt3-itd point mutat activ loop flt3-alm juvenil myelomonocyt leukemia jmml rare myelodysplast/myeloprolif disord earli childhood mutat genet abnorm ra nf1 ptpn11 implic caus event jmml approxim jmml patient harbor none abnorm investig whether flt3 mutat contribut jmml pathogenesi present whether flt3 statu correl diseas natur histori prognosi procedur genom dna isol peripher blood bone marrow sampl patient meet intern jmml diagnost criteria sampl analyz flt3-itd flt3-alm us polymeras chain reaction restrict endonucleas digest result flt3-alm found 1/60 1.7 patient analyz direct sequenc confirm c836g mutat clinic laboratori characterist jmml patient flt3-alm differ remaind cohort flt3-itd mutat detect conclus first report mutat analysi both flt3-itd flt3-alm perform jmml document presenc flt3 mutat jmml suffici low preval clinic insignific most patient despit poor prognosi limit therapeut option jmml patient refractori diseas compassion therapi target flt3 inhibitor consid patient popul adequ safeti efficaci data becom avail
soto syndrom overgrowth disord manifest characterist dysmorph featur neurolog problem increas risk cancer heart defect alter nsd1 respons diseas subset case aris delet interest factor xii locu li close proxim nsd1 case report describ individu soto syndrom factor xii defici provid potenti link two gene consequ expand clinic phenotyp soto syndrom
background studi initi test hypothesi solubl p185 her-2 valu diagnost predict marker patient malign bone tumour procedur sera patient high-grade malign osteosarcoma ew sarcoma test time diagnosi elisa compar sera control clinic data result patient osteosarcoma ew sarcoma level sp185 her-2 differ significantli level control result irrespect type tumour surviv chemotherapi clinic variabl conclus p185 her-2 serum level appear diagnost predict valu differenti high-grade osteosarcoma ew sarcoma
purpos review comprehens literatur review 200 origin manuscript publish month conduct summar landmark studi perform molecular biologi diagnosi imag treatment endocrin tumor pancrea recent find recent achiev occur front identif novel insulin splice variant increas translat effici move forward understand molecular biologi insulinoma result 29-year prospect studi nation institut health clarifi epidemiolog multipl endocrin neoplasia-1 syndrom chromogranin identifi promis marker pancreat endocrin tumor imag includ f-dopa positron emiss tomographi laparoscop ultrasound effect combin exist modal local stage tumor greater accuraci nonop treatment strategi show promis discoveri antiangiogen properti octreotid overexpress tyrosin kinas receptor c-kit epiderm growth factor receptor platelet-deriv growth factor receptor malign endocrin pancreat tumor lead promis pharmacolog treatment summari excit recent advanc research surround endocrin pancrea hopefulli will pave wai potenti improv clinic outcom patient tumor
aim studi assess frequenc clinic characterist cytosin arabinosid-induc fever patient acut myeloid leukemia remiss receiv high-dose g/m2 consolid therapi investig consolid cycl studi period year strict definit cytosin arabinosid-induc fever i.e patient neutropenia neg blood cultur fever episod us consolid cycl fever due cytarabin detect cycl median time onset fever first chemotherapi dose maximum temperatur rang 38.0-39.7 degre mean+/-sd 38.8+/-0.5 degre median durat fever 10.15 exce differ regard neutrophil white blood cell count cycl cytarabin fever cost investig fever sourc us$2137 analysi suggest 'cytarabin fever' frequent self-limit complic high-dose cytosin arabinosid consolid therapi cost-reduct approach structur base background
three steroid ester common alkyl agent chlorambucil's activ metabolit phe phe studi regard genet activ human lymphocyt cultur treat vitro cytokinesi block micronucleu assai us combin fluoresc situ hybrid cytosin arabinosid method ara-c aim studi examin modifi analog ea-72 sot-19 parent compound as exert same genet activ as correl genet activ chemic structur investig whether steroid ester abl induc excis repair lesion through alkyl dna iii collect data order evalu exact role steroid skeleton express antileukem activ found phe steroid ester cytotox human lymphocyt cultur indic reduct cytokinesi block prolifer index phe most cytotox molecul studi compound capabl induc both chromosom breakag chromosom delai indic increas cmn cmn frequenc steroid deriv gave reduc genet activ conjug keton ring steroid skeleton result decreas genet activ mainli due decreas chromosom delai studi compound capabl induc dna excis repair
heterotyp hybrid creat dendrit cell tumor cell repres effici approach load tumor-associ antigen taa dc-tumor hybrid vaccin shown promis outcom variou preclin clinic studi convent dc-tumor hybrid prepar howev unavoid contamin dc-tumor aggreg load tumor cell debri here describ strategi select genuin dc-tumor hybrid hat-sensit/zeocin-resist clone xs106-7 zeo fuse gfp-transduc fibrosarcoma clone s1509a-gfp polyethylen glycol heterotyp hybrid clone establish limit dilut presenc hat zeocin cd45 origin gfp tumor origin both express 51/56 clone result clone indic high effici strategi mark heterogen observ among hybrid clone on clone exhibit characterist featur cd86 i-a express dendrit morpholog cell-stimulatori capac il-1beta il-6 tnfalpha product suggest small fraction dc-tumor hybrid acquir maintain properti parent final vaccin hybrid clone protect mice subsequ growth s1509a tumor cell document vivo activ dc-tumor hybrid complet absenc exogen taa
object estim us serum tumor marker' monitor predictor gastric cancer patient pernici anemia patient method investig serum level carcinoembryon antigen cea alpha-fetal protein cancer antigen -19.9 ca-125 ca-15.3 patient pernici anemia healthi control match ag sex patient evalu repeat 1-6 month correct cobalamin defici result patient control normal serum cea alpha-fp level marker well ca-125 ca-19.9 differ two group patient control exhibit increas serum ca-15.3 differ two group signific 129.4 +/- 84.9 19.8 +/- 7.3 iu/ml &lt 0.001 differ male femal found thorough clinic examin patient mammograph studi femal reveal find suspici breast cancer ca-15.3 level posit correl serum lactat dehydrogenas neg hemoglobin substanti decreas correct anemia patient test restor normal median follow-up month on patient develop colon cancer none show sign suspici breast cancer conclus serum ca-15.3 show aberr increas untreat patient pernici anemia revers correct anemia possibl origin seem unrel mammari tissu releas apoptos bone marrow megaloblast erythroblast
t-cell acut lymphocyt leukemia t-all inhibitor cyclin-depend kinas cdk p16 p15 inactiv almost univers dna rna protein level suggest cdk-target effect therapeut approach t-all cancer studi test inhibitor cdk4 3-aminothioacridon 3-ata thioacridon oxindol effect dna synthesi viabil primari t-all compound effect inhibitor overal similar rang coloni format assai leukem cell approxim 10-fold sensit 3-ata normal bone marrow cell sort protein statu t-all p16 p15 prb sampl significantli sensit 3-ata oxindol p16 p15 prb sampl relationship sensit arf express despit vitro function inhibitor cdk4 3-ata inhibit prb phosphoryl caus arrest caus dna damag result induct phosphoryl p53 conclud 3-ata efficaci predict p16 statu t-all mechan action distinct vitro abil regul cdk4 kinas activ
human atp-bind cassett abc transport gene classifi seven sub-famili subfamili compris total gene member abcc10 cdna clone human full-length cdna project kazusa dna research institut howev current inform limit regard physiolog function gene express present studi investig express abcc10 gene gain insight biolog natur quantit pcr abcc10 gene express demonstr highest pancrea among adult fetal tissu tumor present test decreas express observ rest b-cell activ furthermor examin express under apoptot condit found abcc10 mrna level remark increas doxorubicin-treat mcf7 cell wherea up-regul suppress p53-domin-neg mcf7 cell result suggest express abcc10 gene regul p53-depend manner dna-damag-relat apoptosi
plan therapi acut myelogen leukemia aml difficult becaus heterogen natur diseas vari patient ag present cytogenet patient ag time diagnosi two major factor determin treatment outcom aml patient poor-risk cytogenet much lower complet remiss rate group addit aml patient greater year ag exhibit resist phenotyp akin secondari aml aml aris myelodysplast syndrom group character lower complet remiss rate requir deliveri intens therapi patient popul least like toler jefferson health system philadelphia wish develop regimen maxim intens treat stubborn diseas gentl enough given patient regardless ag patient receiv maxim dose cytoprotect agent amifostin befor infus idarubicin regimen escal dose idarubicin phase fashion maximum dose mg/m2 data indic addit amifostin aml induct therapi enabl substanti escal idarubicin dose through 21-mg/m2 dose level concomit increas side effect provid regimen both intens applic patient ag current phase studi ongo nation basi evalu efficaci regimen
puls oximetri valuabl non-invas method us estim oxyhaemoglobin satur give bedsid indic oxygen provid valuabl insight caus breathless us help palli care team determin need prescrib withhold oxygen therapi technolog well establish rel inexpens factor influenc read includ low perfus state life thorough understand us limit puls oximetri assist multidisciplinari team provid better care ill patient palli care set
accur detect abnorm clone children persist cytopenia confirm diagnosi myelodysplast syndrom md determin prognosi evolut diseas bone marrow sampl obtain children final diagnos primari secondari md ten g-band metaphas analyz fish perform us a-satellit probe chromosom convent cytogenet analysi cca success 40/65 sampl reveal clonal aberr patient md fish success case detect monosomi trisomi abnorm clone patient abnorm identifi 3/6 children primari md 3/5 secondari md none patient etiolog md clonal abnorm result confirm high incid chromosom abnorm childhood md sensit fish detect minor abnorm clone
background plasma epstein-barr viru dna ebv-dna level found indic stage prognosi nasopharyng carcinoma npc materi method ebv-dna level plasma peripher blood cell pbc neoplast tissu quantit analyz potenti associ clinic paramet npc investig result plasma ebv-dna detect rate level npc 500 copi/ml significantli higher npc treatment copi/ml control copi/ml &lt 0.001 signific pbc ebv-dna detect rate ebv-dna load npc befor copi/actin treatment copi/actin control copi/actin plasma ebv-dna level correl pbc ebv-dna load npc befor 0.92 treatment 0.267 control 0.735 ebv-dna level npc tumor 27.8 copi/actin significantli higher nasopharyng posit correl ratio eber1-posit cell npc section 0.001 plasma ebv-dna level significantli increas tnm stage iii npc wherea signific differ pbc ebv-dna load differ stage npc conclus result indic plasma ebv-dna sensit reliabl biomark pbc ebv-dna diagnosi stage therapeut effect evalu molecular level npc clinic practic plasma ebv-dna deriv cancer cell pbc ebv-dna circul mononuclear cell npc patient
background purpos studi investig whether cycl-relat variat circul vascular endotheli growth factor vegf level increas metastat potenti specif time menstrual cycl materi method vegf level serum whole blood evalu normal menstrual cycl premenopaus women determin menstrual phase base hormon measur result total sampl taken six menstrual cycl serum vegf invers relat progesteron level -0.6 0.012 menstrual cycl serum vegf decreas indic lowest vegf level occur secretori phase compat invers relationship serum progesteron vegf conclus find howev suggest individu vegf level direct optim time surgic intervent breast cancer
silver-stain nucleolar organ region agnor perform patient acut lymphoblast leukemia verifi role cell prolifer predict complet remiss surviv bone-marrow aspir smear pediatr case stain argyrophil method diagnosi remiss 3rd 6th 9th 12th month remiss mean nor count norsc mean nucleolar organ region surfac/total nuclear surfac 100 valu norss/tn case calcul diagnosi norsc norss/tn valu whole seri 3.30+/-0.86 4.77+/-1.15 respect complet remiss norsc norss/tn valu 1.23+/-0.20 3.45+/-0.87 respect differ statist highli signific &lt .001 most import paramet prognost factor effect diagnosi norss/tn norsc valu found fab morpholog leukocyt count accord multivari analysi test agnor analysi suitabl method assess cell prolifer bone marrow aspir predict complet remiss remiss durat surviv pediatr patient
poland syndrom sporad associ hematolog condit primarili acut leukemia author report child syndrom coexist temporari hematolog dysplasia due iron defici hematolog evalu fail demonstr malign becaus premalign natur patient poland syndrom hematolog dysplast featur indic investig howev addit well-known hematolog malign treatabl caus respons
peripher blood mononuclear cell pbmc patient npc immun vitro anti-npc monoclon antibodi fc2 transform epstein-barr viru ebv detect show npc patient patient' cell immun fc2 transform ebv produc anti-idiotyp antibodi npc five type gene type gene obtain rt-pcr amplif connect gly4ser linker form type scfv gene scfv gene digest sfi clone vector fuse5 transform coli 1061 phage anti-idiotyp antibodi librari 1.5 clone obtain four round pan 270 phage clone select randomli fc2-posit clone obtain sandwich elisa posit ratio 33.7 clone d83 e92 g22 i50 i54 displai beta type ab2 scfv select bind inhibit test phage anti-idiotyp antibodi analyz dna sequenc vdj region g22 i50 i54 belong vh4-39-d4-11-jh3-linker-v1-19-jl2 vh4-4-d4-11-jh6 vh4-31-d4-11-jh6 respect e92 same vdj region g22 d83 same vdj region 150 strategi prepar select beta type ab2 scfv cdr mean immun vitro ebv transform phage displai techniqu feasibl pave wai prepar cancer vaccin us beta type ab2 scfv
benjamin castleman first describ multicentr castleman's diseas mcd seri case 1954 interest mcd grown recent year associ human immunodefici viru hiv infect castleman's diseas separ local diseas mcd latter character polylymphadenopathi multiorgan involv histolog castleman's diseas divid hyalin vascular form plasma cell variant former common local diseas latter common mcd mcd associ kaposi's sarcoma herpesviru kshv infect altern term human herpesviru hhv8 viru encod homologu interleukin vil mediat system featur mcd diagnosi castleman's diseas establish biopsi treatment base publish case report random trial therapi surgeri role mcd local diseas debulk splenectomi us allevi haematolog sequela system treatment mcd includ chemotherapi anti-herpesviru treatment reduc kshv viral load highli activ antiretrovir therapi haart reduc hiv viraemia latterli monoclon antibodi both cd20 introduct haart alter natur histori hiv infect howev impact mcd difficult ascertain optim consensu treatment patient remain target futur
on experiment studi examin effect haemodilut circulatori respons hyperthermia publish inform respiratori respons hyperthermia haemodilut anaemia paper studi effect acut normovolem haemodilut cardiorespiratori chang degre hyperthermia recoveri bodi surfac cool anaesthet adult rabbit anim divid two group haemodilut group hct 18.6 +/- 0.4 control group hct 41.1 +/- 0.9 haemodilut group acut normovolem haemodilut induc replac total blood volum dextran haemodilut produc signific increas minut volum &lt 0.02 heart rate &lt 0.02 central venou pressur cvp &lt 0.02 signific chang mean arteri pressur map hyperthermia caus signific increas both group howev valu significantli higher haemodilut group compar control cvp decreas &lt 0.05 degre hyperthermia control pant phase map significantli chang over-heat control significantli &lt 0.02 rose haemodilut group recoveri phase cool led signific decreas map both group increas &lt 0.05 control wherea decreas haemodilut anim found signific cardiorespiratori differ two group cool hyperthermia accompani higher valu minut volum heart rate haemodilut anim indic greater activ respiratori cardiovascular system result diminish function cardiorespiratori reserv higher risk respiratori circulatori failur haemodilut/anaem anim hyperthermia phase recoveri bodi temperatur signific cardiorespiratori differ found two group
object explor possibl associ polymorph glutathion s-transferas gene leukemia suscept method as-pcr procedur appli determin gst genotyp group leukemia patient shanghai area genotyp frequenc leukemia patient normal control 183 healthi resid same citi compar stratif leukemia type ag gender made comparison result frequenc gstt1 0/0 genotyp gstt1 0/0-gstm1 0/0 combin genotyp higher leukemia patient control differ signific stratifi ag gender trend still exist male patient younger patient ag &lt conclus individu bear gstt1 0/0 genotyp gstt1 0/0-gstm1 0/0 combin genotyp suscept leukemia especi male younger carrier
import epigenet modif carcinogenesi sourc controversi time littl doubt chang genom hypermethyl contribut silenc tumor suppressor gene furthermor recent studi identifi signific genom hypomethyl associ chromosom instabl tumorigenesi on most perplex question regard epigenet modif leukemogenesi relationship dna methyltransferas dnmt's primari function dnmt enzym methyl genom dna wherea methyl-cpg bind domain protein mbd interpret methyl signal regul gene express chromatin behavior studi analys gene famili quantit real-time pcr investig whether express level b-cell chronic lymphocyt leukemia b-cll phenotyp associ furthermor given epigenet crosstalk genom stabil histon chromatin code analys eukaryot histon methyltransferas eu-hmtasei surprisingli observ signific chang dnmt1 express b-cll case compar normal lymphocyt regardless whether normalis gapdh pcna refer standard inde express mainten novo methylas independ regul particular note signific down regul dnmt3b furthermor observ posit correl hmtasei express level stage leukemia suggest chang methyl pattern b-cll repres deregul epigenet repertoir includ methyl depend bind protein mbd2 mecp2 envisag chang epigenet program multifactori natur postul preval genom methylas just on compon larger epigenet repertoir
anthracyclin topoisomeras inhibitor us variou malign us limit cardiotox three type cardiotox distinguish acut sub-acut chronic chronic toxic relat peak plasma concentr cumul dose gener free radic appear main caus myocardi damag late-onset cardiotox anthracyclin toxic exacerb pediatr elderli popul increas toxic observ heart irradi chemotherapi combin myocardi damag asymptomat long time echocardiographi detect reduct left ventricular eject fraction endomyocardi biopsi specif test earli diagnosi anthracyclin-induc toxic cardiotox reduc anthracyclin administr modif pharmacolog cardioprotect doxorubicin analogu better toler profil epirubicin liposom anthracyclin
background cytokin import signal cell tissu constitut humor compon respons cell tissu radiotherapi sever cytokin implic mediat radiat-induc reaction normal tissu both convent photon heavi ion irradi mechan elucid materi method publish own data radiat-induc cytokin express cell cultur clinic studi review current model cytokin-mediat multicellular interact radiat-induc reaction present result conclus major cytokin radiat respons non-hemopoiet tissu includ il-6 il-1 tnf-alpha tgf-beta differ cell type interact via cytokin complex network effector receptor cell includ inflammatori cell tissu-specif function cell fibroblast tgf-beta appear particular import develop late reaction radiat therapi fibrosi respons both convent therapi well hadron therapi
semi-quantit express analysi both aml1-a aml1-total perform rt-pcr children acut lymphoblast leukemia diagnosi aml1-a express assess bone marrow peripher blood sampl wherea aml1-total assess sampl analys carri sampl healthi control addit 18/19 patient karyotyp unmodifi constitut karyotyp seven exhibit acquir chromosom abnorm aca express aml1-a significantli increas compar control &lt 0.013 &lt 0.035 respect signific increas found express aml1-a aca group compar group &lt 0.0009 express aml1-a show signific increas aca group compar control &lt 0.00001 &lt 0.012 respect contrast group differ control observ mean increas aml1-a favour progress leukemia
chronic myeloid leukemia myeloprolif disord character presenc philadelphia chromosom extramedullari blast crisi rare event imatinib mesyl becom treatment choic especi patient allogen stem cell transplant option imatinib produc complet cytogenet respons excess howev penetr drug metabolit cn central nervou system poor henc patient prolong imatinib therapi continu complet cytogenet respons central nervou system becom sanctuari site report patient complet hematolog cytogenet respons present headach vomit mri show mening enhanc csf cerebro spinal fluid examin posit blast start cranial radiotherapi tripl intrathec chemotherapi show good symptomat improv clear blast csf radiat complet hematolog remiss marrow metaphas posit philadelphia chromosom match sibl donor dose imatinib increas 600 daili continu complet hematolog remiss time report
explos anticoagul recent year parenter anticoagul develop overcom limit heparin low molecular weight heparin wherea novel oral activ anticoagul design provid streamlin therapi vitamin antagonist focus drug advanc stage clinic test review identifi molecular target anticoagul describ result clinic trial provid perspect opportun anticoagul
purpos kaposiform-hemangioendothelioma khe rare vascular tumor develop predominantli infant children.despit benign histolog tumor frequent behav aggress caus signific morbid mortal.the strike resembl spindl cell prolifer kaposi sarcoma led design khe rare lesion.thi work examin histopatholog featur khe assess valu vascular immunohistochem marker cd34 cd31 factor viii associ antigen routin diagnosi differenti diagnosi vascular tumor materi method three case khe twenti case includ studi.all specimen fix formalin embed paraffin wax stain hematoxlin eosin reticulin stain.the antibodi cd34 cd31 factor viii associ antigen appli us streptavidin biotin techniqu result immunohistochem elememt lesion label anti-cd34 antibodi label spindl cell consist anti-cd31 antibodi factor viii associ antigen label well form capillari conclus khe tumor endotheli cell origin immuno-stane cd34 lesser extend cd31 reliabl label khe tradit endotheli cell marker factor viii associ antigen marker us diagnosi routin process tissu khe
chronic myelogen leukemia cml clonal bone marrow diseas progress chronic phase aggress blast crisi cell line nalm-1 origin establish minowada cowork peripher blood patient cml blastic crisi karyotyp analysi nalm-1 cell line perform 1970s best knowledg karyotyp re-analyz molecular cytogenet techniqu cell line sourc molecular investig includ express studi establish cell line cml control own laboratori nalm-1 analyz gtg band fluoresc situ hybrid spectral karyotyp result differ origin public sonta cowork describ first time karyotyp nalm-1 cell line der q10 q15 der p24 q33 approxim q34 q34 q11 der q15 der q34 q11
